UBS Maintains Buy on Ascendis (ASND), Sees Upside from Yorvipath Data

Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best biotech stocks to buy. UBS reaffirmed its 307 price target and Buy rating on Ascendis Pharma A/S (NASDAQ:ASND) on September 23 in response to MBX’s clinical study for the treatment of persistent hypoparathyroidism.

Given Yorvipath’s higher placebo-adjusted response rates of 52.9% at 4 weeks and 69% at 26 weeks in its clinical trials, UBS maintains that Ascendis Pharma’s medication continues to lead the hypoparathyroidism treatment space, despite supportive rival data.

In what it considers to be a sizable market worth over $10 billion, UBS sees upside potential for Yorvipath sales both in the short and medium run and sees the MBX data release as relieving an overhang for Ascendis Pharma A/S (NASDAQ:ASND).

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and distributes novel treatments for unmet medical needs, especially in the fields of oncology and endocrinology.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.